Joana Sederias
Overview
Explore the profile of Joana Sederias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta A, Tinker A, Jonker D, Jamal R, Hirte H, Winquist E, et al.
EClinicalMedicine
. 2024 Dec;
79:102991.
PMID: 39737219
Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought...
2.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2024 Aug;
19(11):1578-1579.
PMID: 39186030
No abstract available.
3.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo M, Grosso F, et al.
Lancet
. 2023 Nov;
402(10419):2295-2306.
PMID: 37931632
Background: Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum-pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum-pemetrexed would improve overall survival...
4.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2023 Feb;
18(6):813-819.
PMID: 36841541
Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro)...
5.
LaPointe S, Mason W, MacNeil M, Harlos C, Tsang R, Sederias J, et al.
Invest New Drugs
. 2019 Nov;
38(4):1137-1144.
PMID: 31707687
The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies. Inhibition of the PI3K pathway has been shown to...
6.
Bradbury P, Morris D, Nicholas G, Tu D, Tehfe M, Goffin J, et al.
Lung Cancer
. 2018 May;
120:142-148.
PMID: 29748010
Objectives: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy. We evaluated pelareorep, combined with standard second-line chemotherapy in...
7.
Seftel M, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, et al.
Leuk Lymphoma
. 2016 Oct;
58(6):1358-1365.
PMID: 27750483
AT7519M is a small molecule inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies. In two concurrent Phase II trials, we evaluated...
8.
Hay A, Murugesan A, DiPasquale A, Kouroukis T, Sandhu I, Kukreti V, et al.
Leuk Lymphoma
. 2015 Sep;
57(6):1463-6.
PMID: 26376958
No abstract available.
9.
Oza A, Elit L, Tsao M, Kamel-Reid S, Biagi J, Provencher D, et al.
J Clin Oncol
. 2011 Jul;
29(24):3278-85.
PMID: 21788564
Purpose: Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss...
10.
MacKay H, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, et al.
Gynecol Oncol
. 2009 Sep;
116(2):163-7.
PMID: 19740535
Objective: Vascular endothethial growth factor (VEGF) and stem cell factor (c-KIT) signaling may play a role in the development and progression of cervical carcinoma. Sunitinib malate is an oral, multi-targeted...